Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Colorcon
Baxter
Moodys
McKesson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0917

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for GDC-0917?

GDC-0917 is an investigational drug.

There have been 165 clinical trials for GDC-0917. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are three US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for GDC-0917
TitleSponsorPhase
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the BonesNational Cancer Institute (NCI)Phase 2
A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerHoffmann-La RochePhase 2/Phase 3

See all GDC-0917 clinical trials

Clinical Trial Summary for GDC-0917

Top disease conditions for GDC-0917
Top clinical trial sponsors for GDC-0917

See all GDC-0917 clinical trials

US Patents for GDC-0917

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0917   Start Trial Inhibitors of IAP Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0917   Start Trial Inhibitors of IAP GENENTECH, INC. (South San Francisco, CA)   Start Trial
GDC-0917   Start Trial Inhibitors of IAP GENENTECH, INC. (South San Franscisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Johnson and Johnson
AstraZeneca
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.